Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept as First-line Immunosuppression in De Novo Liver Transplant Recipients
2007-002125-68Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of belatacept in liver transplant recipient (LTR) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of acute rejection, graft loss, and death by 6 months. Started Oct 2007; status: terminated.
02
Drugs
belatacept
03
Conditions
liver transplant recipient (LTR)
Beyond the preview
Go deeper on 2007-002125-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002125-68.